Paper
First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma

https://doi.org/10.1016/0959-8049(95)00063-OGet rights and content

Abstract

33 previously untreated advanced stage neuroblastoma patients were treated with [131I] meta-iodobenzylguanidine (MIBG). The number of treatments varied between 2 and 7 per patient (mean 3). Toxicity was seldom severe. Only thrombocytopenia WHO-grade 4 was noticed. Response was documented before surgery for the primary tumour was performed. There was one complete response (CR), 18 partial responses (PR), 11 had stable disease (SD) and 3 had progressive disease (PD). After MIBG therapy and surgery, 12 of 33 patients achieved a CR. This approach is feasible, comparable to multidrug chemotherapy in efficacy and less toxic. Long term results are not known yet.

References (13)

  • JO Morales et al.

    The concentration of radioactivity for labelled epinephrine and its precursors in the dog adrenal medulla

    J Nucl Med

    (1967)
  • JC Sisson et al.

    Scintigraphic localization of pheochromocytoma

    New Engl J Med

    (1981)
  • B Shapiro et al.

    Iodine-131 metaiodobenzylguanidine for the location of suspected pheochromocytoma: experience in 400 cases

    J NuclMed

    (1985)
  • JC Sisson et al.

    Radiopharmaceutical treatment of malignant pheochromocytoma

    J Nucl Med

    (1984)
  • CA Hoefnagel et al.

    Radionuclide diagnosis and treatment of neural crest tumors using iodine-131-meta-iodobenzylguanidine

    J Nucl Med

    (1987)
  • S Jaques et al.

    Mechanisms of uptake of norepinephrine (NE) and meta-iodobenzylguanidine (MIBG) into cultured human pheochromocytoma cells

    J Nucl Med

    (1984)
There are more references available in the full text version of this article.

Cited by (71)

  • <sup>131</sup>I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications

    2016, Seminars in Nuclear Medicine
    Citation Excerpt :

    Multiple investigations have explored ways to increase therapeutic 131I-mIBG efficacy through combinations that enhance norepinephrine transporter (NET) expression.77-90 More recently, 131I-mIBG has been used as a “front-line” therapeutic agent in those without relapsed or recurrent disease in Dutch and Italian neuroblastoma trials as well as a “front-line” agent administered at the end of induction in the COG ANBL09P1 trial.91-96 Figure 11 depicts the time frames and several of the major trials using 131I-mIBG therapy for neuroblastoma; these major trials and their findings are discussed in the subsequent sections.

View all citing articles on Scopus
View full text